Massimiliano Bissolati

Massimiliano Bissolati

Auto-generated profile, based on publicly available information

Massimiliano Bissolati

Department of Surgery, San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2015 in Gut
Verified
Journal Article
Closed access
PDF file
BJB Jais
B Jais
VRV Rebours
V Rebours
GMGiuseppe Malleo
Giuseppe Malleo
RSRoberto Salvia
Roberto Salvia
MFM Fontana
M Fontana
PLP Lévy
P Lévy
Objectives Serous cystic neoplasm (SCN) is a cystic neoplasm of the pancreas whose natural history is poorly known. The purpose of the study was to attempt to describe the natural history of SCN, including the specific mortality. Design Retrospective multinational study including SCN diagnosed between 1990 and 2014. Results 2622 patients were included. Seventy-four per cent were women, and median age at diagnosis was 58 years (16–99). Patients presented with non-specific abdominal pain (27%), pancreaticobiliary symptoms (9%), diabetes mellitus (5%), other symptoms (4%) and/or were asymptomatic (61%). Fifty-two per cent of patients were operated on during the first year after diagnosis (median size: 40 mm (2–200)), 9% had resection beyond 1 year of follow-up (3 years (1–20), size at diagnosis: 25 mm (4–140)) and 39% had no surgery (3.6 years (1–23), 25.5 mm (1–200)). Surgical indications were (not exclusive) uncertain diagnosis (60%), symptoms (23%), size increase (12%), large size (6%) and adjacent organ compression (5%). In patients followed beyond 1 year (n=1271), size increased in 37% (growth rate: 4 mm/year), was stable in 57% and decreased in 6%. Three serous cystadenocarcinomas were recorded. Postoperative mortality was 0.6% (n=10), and SCN's related mortality was 0.1% (n=1). Conclusions After a 3-year follow-up, clinical relevant symptoms occurred in a very small proportion of patients and size slowly increased in less than half. Surgical treatment should be proposed only for diagnosis remaining uncertain after complete workup, significant and related symptoms or exceptionally when exists concern with malignancy. This study supports an initial conservative management in the majority of patients with SCN. Trial registration number IRB 00006477.

16 October 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
MBMassimiliano Bissolati
Massimiliano Bissolati
MSMaria Teresa Sandri
Maria Teresa Sandri
GBGiovanni Burtulo
Giovanni Burtulo
LZLaura Zorzino
Laura Zorzino
Gianpaolo BalzanoGianpaolo Balzano
Gianpaolo Balzano
MBMarco Braga
Marco Braga

25 November 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AVAndrea Volonté
Andrea Volonté
TTTiziano Di Tomaso
Tiziano Di Tomaso
MSMichela Spinelli
Michela Spinelli
MTMatilde Todaro
Matilde Todaro
FSFrancesca Sanvito
Francesca Sanvito
Cristina MaccalliCristina Maccalli
Cristina Maccalli
Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display “tumor-initiating/stemness” properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immunomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients.


1 July 2017 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
SCStefano Crippa
Stefano Crippa
Raffaele PezzilliRaffaele Pezzilli
Raffaele Pezzilli
MBMassimiliano Bissolati
Massimiliano Bissolati
Gabriele CapursoGabriele Capurso
Gabriele Capurso
LRLuigi Romano
Luigi Romano
MFMassimo Falconi
Massimo Falconi
To evaluate the results of active surveillance beyond 5 years in patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) without worrisome features (WF) and high-risk stigmata (HRS) undergoing non-operative management. Patients with a minimum follow-up of 5 years who underwent surveillance with at least yearly magnetic resonance imaging were included. New onset of and predictors of WF/HRS during follow-up as well as long-term survival were analyzed. In all, 144 patients were followed for a median of 84 months. At diagnosis multifocal BD-IPMNs were found in 53% of cases and mean size of the largest cyst was 15.5 mm. Changes during follow-up were observed in 69 patients (48%). New onset of WF/HRS were observed in 26 patients (18%) but the rate of HRS was only 4%. WF and HRS developed after a median follow-up of 71 and 77.5 months from diagnosis, respectively, and without previous changes in 19/26 patients. Independent predictors of WF/HRS development were size at diagnosis>15 mm, increase in number of lesions, main pancreatic duct growth rate ≥0.2 mm/year, cyst growth rate >1 mm/year. Overall, the rate of pancreatic invasive malignancy was 2% and the 12-year disease-specific survival was 98.6%. Long-term nonoperative management is safe for BD-IPMNs without WF and HRS. Discontinuation of surveillance cannot be recommended since one out of six patients developed WF/HRS far beyond 5 years of surveillance and without previous relevant modifications. An intensification of follow-up should be considered after 5 years.

8 January 2014 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
EOElena Orsenigo
Elena Orsenigo
MBMassimiliano Bissolati
Massimiliano Bissolati
CSCarlo Socci
Carlo Socci
DCDamiano Chiari
Damiano Chiari
FMFrancesca Muffatti
Francesca Muffatti
CSCarlo Staudacher
Carlo Staudacher